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treatment and insufficient treatment, and to deepen mutual 
understanding between health-care professionals and patients 
by making these Guidelines available to the general public. 
These Guidelines were prepared by consensus reached by the 
JSCCR Guideline Committee, based on a careful review of 
the evidence retrieved by literature searches, and in view of 
the medical health insurance system and actual clinical prac-
tice settings in Japan. Therefore, these Guidelines can be used 
Abstract Japanese mortality due to colorectal cancer is on 
the rise, surpassing 49,000 in 2015. Many new treatment 
methods have been developed during recent decades. The 
Japanese Society for Cancer of the Colon and Rectum Guide-
lines 2016 for the treatment of colorectal cancer (JSCCR 
Guidelines 2016) were prepared to show standard treatment 
strategies for colorectal cancer, to eliminate disparities among 
institutions in terms of treatment, to eliminate unnecessary 
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as a tool for treating colorectal cancer in actual clinical prac-
tice settings. More specifically, they can be used as a guide 
to obtaining informed consent from patients and choosing 
the method of treatment for each patient. As a result of the 
discussions held by the Guideline Committee, controversial 
issues were selected as Clinical Questions, and recommenda-
tions were made. Each recommendation is accompanied by 
a classification of the evidence and a classification of recom-
mendation categories based on the consensus reached by the 
Guideline Committee members. Here we present the English 
version of the JSCCR Guidelines 2016.
Keywords Colorectal cancer · Guideline · Surgery · 
Chemotherapy · Endoscopy · Radiotherapy
Introduction
1. Guideline objectives
Incidence and mortality of colorectal cancer have substan-
tially increased in Japan recently. According to the vital 
statistics of Japan in 2015, colorectal cancer accounted for 
the largest number of deaths from malignant neoplasms in 
women. Nevertheless, the number of deaths from colorec-
tal cancer per unit population has increased approximately 
tenfold during the past 50 years. Many new treatment 
methods have been developed during that time, and their 
use in combination with advances in diagnostic methods 
has led to a steady improvement in the results of treatment. 
However, there are differences in treatment among medical 
institutions in Japan that provide medical care for patients 
with colorectal cancer, and the differences may lead to dif-
ferences in the results of treatment.
Under such circumstances, the JSCCR guidelines 2016 
for the treatment of colorectal cancer (JSCCR Guidelines 
2016), which are intended for doctors (general practition-
ers and specialists) who provide medical care for patients 
with colorectal cancer in various disease stages and con-
ditions, were prepared for the following purposes: (1) To 
show standard treatment strategies for colorectal cancer, 
(2) To eliminate disparities among institutions in terms 
of treatment, (3) To eliminate unnecessary treatment and 
insufficient treatment, (4) To deepen mutual understand-
ing between health-care professionals and patients by 
making these Guidelines available to the general public 
[1].
The following are expected to be achieved with these 
Guidelines: (1) Improvement of the treatment of colo-
rectal cancer in Japan; (2) Improvement of the results of 
treatment; (3) Reduction of the human and financial bur-
den; (4) Increased benefits for patients.
2. How to use these guidelines
These Guidelines were prepared by consensus reached by 
the Guideline Committee of the Japanese Society for Can-
cer of the Colon and Rectum, based on a careful review of 
the evidence retrieved by literature searches and in view 
of the medical health insurance system and actual clinical 
practice settings in Japan, and therefore, they can be used 
as a tool for treating colorectal cancer in actual clinical 
practice settings. More specifically, they can be used as a 
guide to obtaining informed consent from patients and 
choosing the method of treatment for each patient. How-
ever, these Guidelines provide only general recommenda-
tions for choosing treatment strategies for colorectal can-
cer, and they do not control or limit treatment strategies 
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or treatment methods that are not described herein. They 
can also be used as a document to explain the rationale for 
selecting treatment strategies and treatment methods that 
differ from those described therein. 
The Japanese Society for Cancer of the Colon and Rec-
tum (JSCCR) is responsible for the statements in these 
Guidelines. However, the personnel directly in charge of 
treatment, not the JSCCR or the Guideline Committee, 
are responsible for the outcome of treatment.
3. Users
The users of these Guidelines are mainly clinical doctors 
engaged in all aspects of the medical treatment of colorec-
tal cancer.
4. How to develop these Guidelines
(1) Recording methods
We adopted the concept from the first edition, in which 
the treatment policy algorithm was disclosed and a simple 
explanation thereof recorded and added further comments 
in regard to categories requiring additional explanation. 
Since the 2009 edition, areas of debate have been raised as 
clinical questions (CQs) and included with recommenda-
tions added. In the 2016 edition, this practice was contin-
ued, with corrections and additions made to the CQs based 
on knowledge acquired since the 2010 version.
(2) Evidence level/strength of recommendations of CQs
The recommendations added to CQs included the evidence 
level and strength of recommendations determined using 
the following direction.
(2-1) Evidence level
Papers relating to the CQs were comprehensively col-
lected, and the evidence indicated by individual papers 
relating to the critical outcomes included within the 
CQs was divided into groups by study design [2]. The 
literature level and a body of evidence (Table 1) were 
evaluated in reference to the GRADE* System [3–
25], before determining the final CQ evidence level 
(Table 2).
*GRADE: The Grading of Recommendations Assess-
ment, Development, and Evaluation.
(2-2) Strength of recommendations
Draft recommendation statements and the strength of the 
recommendations were directed based on the outcomes 
and the level of evidence obtained from the process 
described above and were evaluated at a consensus meet-
ing of the Guideline Committee.
The draft recommendations were evaluated from 
four categories (① Quality of evidence, ② Patients’ 
views and preferences, ③ Benefits and harms, and ④ 
Cost effectiveness). The strength of recommendation 
(Table 3) was determined by vote, based on the Delphi 
method, with those reaching a consensus of opinion of 
70% or more committee members determined as having 
been agreed upon. Items not reaching consensus after a 
single vote were debated once again, with the results of 
the first vote disclosed and additional information on the 
situation relating to clinical practice in Japan provided, 
and discussion and voting was repeated until a consensus 
was reached. No strength of recommendation was pre-
sented in CQs.
Table 1  Rating the quality of 
evidence Step 1 (evaluation of individual study): study design, evaluation of bias risk, create structured abstract
Step 2 (overall rating for each important outcome across studies)
1. Initial quality of a body of evidence: evaluation of each study design group
 systematic reviews, meta-analysis, randomized controlled trials = “initial quality A (high level)”
 observation studies, cohort studies, case control studies = “initial quality C (low level)”
 case series, case reports = “initial quality D (very low level)”
2. Five reasons to possibility rate down the quality
 risk of bias
 inconsistency in results
 indirectness of evidence
 data imprecision
 high possibility of publication bias
3. Three reasons to possibility rate up the quality
 large effect with no confounding factors
 dose–response gradient
 possible confounding factors are weaker than actual effects
4. We evaluate 1 → 2 → 3, and assess the quality of a body of evidence
 Int J Clin Oncol
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5. Literature search
At first, the literature search was performed for the fol-
lowing 12 broad categories. Then a further search was 
done as needed with additional search techniques.
 (1) Endoscopic treatment of colorectal cancer
 (2) Treatment of Stage 0 to Stage III colorectal cancer 
[26]
 (3) Treatment of Stage IV colorectal cancer [26]
 (4) Treatment of liver metastases of colorectal cancer
 (5) Treatment of lung metastases of colorectal cancer
 (6) Treatment of recurrent colorectal cancer
 (7) Adjuvant chemotherapy for colorectal cancer
 (8) Chemotherapy for unresectable colorectal cancer
 (9) Adjuvant radiotherapy for colorectal cancer
 (10) Palliative radiotherapy for colorectal cancer
 (11) Palliative care for colorectal cancer
 (12) Surveillance after surgery for colorectal cancer
In order to survey the latest literature, in addition to 
the papers used for reference in the previous edition, the 
PubMed and Ichushi-Web databases were selected for 
the search, and the English and Japanese literature was 
searched in both databases from January 2008 to March 
2012. However, the end of the search period for (7) and 
(8) was July 2016. The task of searching was shared by 
four members of the medical library; the four members 
created a search formula by discussion with the com-
mittee members in charge of each item and collected lit-
erature during the search period. In addition, secondary 
documents such as UpToDate and literature collected by 
manual searching were added and critically examined 
as needed, and other documents such as minutes and 
guidelines were included as necessary. We selected 2320 
documents from among the 12,000 documents (PubMed 
7909, ICHUSHI 4091) collected during the literature 
search and critically reviewed all of them (Table 4).
Treatment guidelines for colorectal cancer
Chapter 1: Treatment strategies for Stage 0 to Stage III 
colorectal cancer [26]
1. Endoscopic treatment (Fig. 1)
General principles underlying the indications for endo-
scopic resection.
•	 There is little possibility of lymph node metastasis, and 
the size and location of the tumor make en bloc resec-
tion possible.
Indication criteria for endoscopic resection:
(1) Intramucosal carcinoma or carcinoma with slight 
submucosal invasion
(2) Size does not matter
(3) Any macroscopic type
•	 Endoscopic treatment is a method of endoscopically 
resecting lesions in the large bowel and of collecting the 
resected specimens.
•	  Endoscopic treatment methods consist of polypectomy 
(note 1), endoscopic mucosal resection (EMR) (note 2), 
and endoscopic submucosal dissection (ESD) (note 3).
•	  In determining the indication for endoscopic treatment 
and the treatment method, information on the size, pre-
dicted depth of invasion, and morphology of the tumor 
is essential.
Comments
① Endoscopic resection is intended for both diagnosis 
and treatment. It consists of total excisional biopsy in 
which curability and the necessity of additional intes-
tinal resection are assessed by histopathological exam-
ination of the resected specimens. (CQ-1)
Table 2  Definition of levels of evidence (Reference [13])
A (high) We are very confident in the effect estimate
B (moderate) We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different
C (low) Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
D (very low) We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of 
effect
Table 3  Strength of recommendation (Reference [24])
Strength of recommendation
 1 (Strong recommendation) Strong “For” an intervention
Strong “Against” an intervention
 2 (Weak recommendation) Weak “For” an intervention
Weak “Against” an intervention
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② En bloc resection is desirable for accurate diagnosis of 
the status of carcinoma invasion in the resection mar-
gin and the deepest area.
•	 2 cm is the largest size of a tumor that can be easily 
resected en bloc by polypectomy or snare EMR [27]. 
(CQ-2)
•	 Colorectal ESD is an “endoscopic resection technique 
which enables en bloc resection of a tumor, regard-
less of size,” which was approved for implementa-
tion under health insurance in April 2014 in regard to 
“early-stage malignant tumors” Given the high likeli-
hood of technically difficult complications (perfora-
tions); however, it should only be implemented after 
sufficient consideration of the level of skill of the 
endoscopist performing the procedure. At present, 
tumors with a diameter between 2-5 cm are covered by 
insurance (CQ-3).
•	 EMRC (EMR using a cap) is reported to involve a 
high risk of perforation when used for colon lesions.
Table 4  Number of scientific articles retrieved and selected
Number of articles 
retrieved
Number of articles 
selected
Number of articles retrieved manually
PubMed Ichushi PubMed Ichushi
(1) Endoscopic treatment of colorectal cancer 811 385 80 40 39
(2) Treatment of Stage 0 to Stage III colorectal cancer 469 285 92 14 12
(3) Treatment of Stage IV colorectal cancer 237 102 97 14 13
(4) Treatment of liver metastases of colorectal cancer 812 357 364 79 25
(5) Treatment of lung metastases of colorectal cancer 96 157 46 35 6
(6) Treatment of recurrent colorectal cancer 688 302 147 29 13
(7) Adjuvant chemotherapy for colorectal cancer 855 450 244 39 47
(8) Chemotherapy for advanced or recurrent colorectal cancer 1062 451 320 53 157
(9) Adjuvant radiotherapy for colorectal cancer 447 95 115 8 27
(10) Palliative radiotherapy for colorectal cancer 708 39 109 6 29
(11) Palliative care for colorectal cancer 278 181 58 18 10
(12) Surveillance after surgery for colorectal cancer 1446 1287 256 57 20
Total 7909 4091 1928 392 398
Fig. 1  Treatment strategies for 
cTis (M) cancer and cT1 (SM) 
cancer
Endoscopic en bloc 
resection is possible 
Endoscopic en bloc 




Surveillance Surgical resection 
cTis (M) cancer 
cT1 (SM) cancer 
cTis (M) cancer or slightly 
invasive cT1 (SM) cancer 
Deep invasive 
cT1 (SM) cance 
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•	 If the preoperative diagnosis is cancer accompanied 
by adenoma (intramucosal carcinoma), a piecemeal 
resection can be performed in regard to the ade-
noma, while avoiding division of the cancerous area. 
It should be noted, however, that piecemeal resection 
is associated with a high incomplete resection rate 
and a high local recurrence rate [27].
Note 1:  Polypectomy—In this method, a snare is placed 
on the stalk of the lesion, and the lesion is electro-
cauterized using a high-frequency current. This 
method is mainly used for protruding lesions
Note 2:  EMR—In this method, the lesion is elevated by 
local injection of a liquid such as physiologi-
cal saline into the submucosa, and the lesion is 
electrocauterized the same as in case of polypec-
tomy. This method includes the snare method [3] 
and EMR using a cap (EMRC). It is mainly used 
for superficial tumors and large sessile lesions
Note 3:  ESD—In this technique, the lesion is elevated by 
local injection of a liquid such as sodium hyalu-
ronate solution into the submucosa of the perile-
sional area; then, circumferential incision of the 
mucosa surrounding the lesion and dissection of 
the submucosa with a special knife and en bloc 
resection are performed [28]. ESD is mainly 
indicated for large tumors, especially for early 
cancers that cannot be resected by EMR.
2. Surgical treatment (Fig. 2)
•	 The extent of lymph node dissection to be performed 
during colorectal cancer surgery is determined based on 
the preoperative clinical findings and on the extent of 
lymph node metastasis and depth of tumor invasion by 
the tumor observed intraoperatively.
•	 If lymph node metastasis is recognized, or suspected 
based on the preoperative/intraoperative findings, D3 
dissection is performed.
•	 If no lymph node metastases are observed based on the 
preoperative/intraoperative diagnostic findings, lymph 
node dissection is performed based on the depth of 
tumor invasion [29].
(1) Lymph node dissection is unnecessary for pTis 
(M) cancer (D0), because pTis (M) cancer is not 
accompanied by lymph node metastasis; how-
ever, D1 dissection can be performed because the 
accuracy of the preoperative diagnosis of inva-
sion depth may be insufficient.
(2) D2 dissection is necessary for pT1 (SM) cancer, 
because the incidence of lymph node metastasis 
is approximately 10% and because pT1 (SM) 
cancer is often accompanied by intermediate 
lymph node metastasis.
(3) Although there is insufficient evidence describ-
ing the extent of lymph node dissection for cT2 
(MP) cancer, at least D2 dissection is neces-
sary. However, D3 dissection can be performed, 
because about 1% of cT2 (MP) cancer is accom-
panied by main lymph node metastases (Table 5) 
and because preoperative diagnosis of depth of 
invasion is not very accurate.
Surgical treatment for rectal cancer:
•	 The principle for radical surgery for rectal cancer is 
TME (total mesorectal excision) or TSME (tumor-spe-
cific mesorectal excision) [30–33].
[Indications criteria for lateral lymph node dissection]
Fig. 2  Surgical treatment strat-
egies for cStage 0 to cStage III 
colorectal cancer




cT1 (SM) cT2 (MP) cT3 (SS, A) 
cT4a (SE) 
cT4b (SI, AI) 
D0*, D1 D2 D3 
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Table 5  Lateral dissection and lateral metastasis of rectal cancer
Project study by the JSCCR: patients in years 1991–1998









rate (percentage of all 
patients)
Lateral metastasis rate (percent-
age of patients who underwent 
lateral dissection)
RS
 sm 124 0 0 0 0.0 0.0
 mp 127 6 4.7% 0 0.0 0.0
 ss/a1 316 24 7.5% 0 0.0 0.0
 se/a2 177 8 4.5% 0 0.0 0.0
 si/ai 32 14 43.8% 1 3.1 7.1
 Total 776 52 6.7% 1 0.1 1.9
Ra
 sm 138 5 3.6% 0 0.0 0.0
 mp 149 18 12.1% 0 0.0 0.0
 ss/a1 230 58 25.2% 4 1.7 6.9
 se/a2 181 59 32.6% 7 3.9 11.9
 si/ai 15 8 53.3% 0 0.0 0.0
 Total 713 148 20.8% 11 1.5 7.4
RaRb + Rb
 sm 234 37 15.8% 2 0.9 5.4
 mp 372 218 58.6% 20 5.4 9.2
 ss/a1 350 230 65.7% 28 7.7 12.2
 se/a2 412 319 77.4% 75 18.0 23.5
 si/ai 59 48 81.4% 17 28.8 35.4
 Total 1427 852 59.7% 142 9.8 16.7
•	 Lateral lymph node dissection is indicated when the 
lower border of the tumor is located distal to the peri-
toneal reflection and the tumor has invaded beyond the 
muscularis propria [30].
[Local excision for rectal cancer]
•	 Local excision is indicated for cTis (M) cancer and cT1 
(SM) cancer (slight invasion) located distal to the sec-
ond Houston valve (peritoneal reflection).
•	 Histological investigation of the resected specimen 
allows a determination to be made of the likelihood 
that treatment will cure the condition completely, 
along with the need for additional treatment (intes-
tinal resection accompanied by lymph node dissec-
tion).
[Autonomic nerve-preserving surgery]
•	 The autonomic nervous system related to surgery 
for rectal cancer consists of the lumbar splanch-
nic nerves, superior hypogastric plexus, hypogastric 
nerves, pelvic splanchnic nerves, and pelvic plexus. 
Considering factors such as the degree of cancer pro-
gression and presence or absence of macroscopic 
nerve invasion, preservation of autonomic nerves 
is attempted in order to preserve urinary and sexual 
functions as much as possible, provided that curabil-
ity is unaffected.
Laparoscopic surgery:
•	 The indications for laparoscopic surgery are deter-
mined by considering the surgeon’s experience and 
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skills, as well as tumor factors, such as the location 
and degree of progression of the cancer, and patient 
factors, such as obesity and history of open abdominal 
surgery. (CQ-4)
Comments
[Lateral lymph node dissection]
① An analysis of 2916 cases of rectal cancer in the pro-
ject study by the JSCCR showed that the lateral lymph 
Table 6  Incidences of lymph 
node metastasis according to 
primary site and depth of tumor 
invasion
National registry of patients with cancer of the colon and rectum of the JSCCR: patients in years 2000–
2004. Depth of invasion and the degree of lymph node metastasis were determined according to the rules 
set forth in the “Japanese Classification of Colorectal Carcinoma” (6th edition)
No. of patients Extent of lymph node metastasis detected histologically
n0 (%) n1 (%) n2 (%) n3 (%) n4 (%)
All sites
 sm 3151 90.7 7.3 1.9 0.0 0.1
 mp 3590 77.3 17.4 4.2 0.9 0.3
 ss/a1 11,272 54.6 29.9 12.0 2.3 1.2
 se/a2 6101 35.9 34.4 20.2 5.7 3.8
 si/ai 1502 43.0 27.6 16.4 6.7 6.3
 Total 25,617 57.1 26.3 11.9 2.9 1.9
Colon
 sm 1957 91.4 6.8 1.8 0.0 0.0
 mp 1747 79.3 16.3 3.5 0.6 0.3
 ss/a1 7333 56.6 28.1 11.7 2.4 1.2
 se/a2 3363 37.4 34.0 19.3 5.6 3.7
 si/ai 960 44.6 28.6 14.7 5.5 6.6
 Total 15,360 58.6 25.4 11.3 2.8 1.8
Rectosigmoid
 sm 337 88.7 9.5 1.8 0.0 0.0
 mp 429 80.4 17.0 2.6 0.0 0.0
 ss/a1 1584 53.9 33.0 10.2 1.3 1.7
 se/a2 789 34.2 38.4 20.8 3.2 3.4
 si/ai 187 44.9 24.6 19.3 4.8 6.4
 Total 3326 55.7 29.3 11.4 1.6 2.0
Rectum
 sm 839 89.7 7.7 2.0 0.1 0.4
 mp 1373 73.9 19.2 5.4 1.4 0.1
 ss/a1 2310 48.8 33.3 14.2 2.7 1.0
 se/a2 1904 33.9 33.6 21.5 6.8 4.1
 si/ai 328 38.1 26.2 19.8 10.4 5.5
 Total 6754 54.3 27.0 13.3 3.6 1.8
Anal canal
 sm 18 94.4 0.0 5.6 0.0 0.0
 mp 41 70.7 9.8 7.3 7.3 4.9
 ss/a1 45 60.0 22.2 8.9 6.7 2.2
 se/a2 46 32.6 21.7 23.9 15.2 6.5
 si/ai 27 33.3 25.9 14.8 18.5 7.4
 Total 177 54.8 17.5 13.0 10.2 4.5
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Table 7  Curative resection rate 
according to stage (lower rows: 
no. of patients)
National registry of patients with cancer of the colon and rectum of the JSCCR: patients in years 2000–
2004
Curative resection rate = Number of patients with histological curability A cancer/Total number of patients 
who underwent surgery
Staging was performed according to the rules set forth in the “Japanese Classification of Colorectal Carci-
noma” (6th edition)
Stage I II IIIa IIIb IV All Stages
All patients 98.7% 96.2% 91.9% 81.8% – 78.0%
5455 7336 5635 2572 4300 25,298
Colon 99.1% 96.6% 92.4% 83.6% – 77.2%
3028 4688 3208 1379 2787 15,090
Rectosigmoid 99.5% 96.6% 92.5% 80.2% – 78.0%
615 961 835 288 560 3259
Rectum 97.9% 95.0% 90.9% 80.5% – 79.9%
1764 1644 1564 866 929 6767
Anal canal 95.8% 86.0% 78.6% 61.5% – 70.9%
48 43 28 39 24 182
Table 8  Cumulative 5-year 
survival rate according to site 
(lower rows: no. of patients)
National registry of patients with cancer of the colon and rectum of the JSCCR: patients in years 2000–
2004
Only adenocarcinomas (including mucinous carcinomas and signet-ring cell carcinomas) were counted
Survival rates were calculated by the life table method with death from any cause as an event
5-year censoring rate = 20.5% (3208/15,667)
Staging was performed according to the rules set forth in the “Japanese Classification of Colorectal Carci-
noma” (6th edition)
Stage 0 I II IIIa IIIb IV All Stages
Cecum 91.0% 93.7% 83.5% 73.0% 65.4% 12.5% 68.2%
79 185 249 207 113 204 1037
Ascending colon 93.9% 91.2% 85.8% 79.1% 63.4% 19.1% 71.4%
125 338 656 416 211 410 2156
Transverse colon 88.9% 91.4% 85.2% 78.5% 65.7% 20.8% 74.0%
105 277 428 244 138 210 1402
Descending colon 100.0% 94.1% 85.3% 82.0% 52.9% 21.1% 75.4%
43 146 224 166 52 117 748
Sigmoid colon 94.2% 92.3% 85.8% 83.0% 64.7% 22.0% 73.7%
154 852 1124 837 363 736 4066
Rectosigmoid 89.4% 91.5% 84.8% 78.0% 60.0% 19.8% 71.6%
54 366 539 473 175 322 1929
Upper rectum 98.0% 95.3% 84.6% 75.9% 57.7% 11.6% 72.4%
67 356 464 471 173 263 1794
Lower rectum 97.5% 88.3% 81.7% 70.0% 51.4% 11.6% 70.5%
142 718 486 473 332 298 2449
Anal canal 100.0% 78.7% 90.9% 46.9% 61.2% 15.7% 60.0%
4 16 14 16 19 17 86
Colon 93.0% 92.3% 85.4% 80.4% 63.8% 19.9% 72.8%
506 1798 2681 1870 877 1677 9409
Rectum 97.6% 90.6% 83.1% 73.0% 53.5% 14.8% 71.3%
209 1074 950 944 505 561 4243
All sites 94.0% 91.6% 84.8% 77.7% 60.0% 18.8% 72.1%
773 3254 4184 3303 1576 2577 15,667
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node metastasis rate in patients whose lower tumor bor-
der was located distal to the peritoneal reflection and 
whose cancer invaded beyond the muscularis propria 
was 20.1% (only patients who underwent lateral lymph 
node dissection) (Table 5). After performing lateral 
lymph node dissection for the above mentioned indica-
tion, it is expected that the risk of intrapelvic recurrence 
decreases by 50%, and the 5-year survival rate improves 
by 8–9% [34].
② The lateral lymph node metastasis rate of patients 
whose lower tumor border was located distal to the 
peritoneal reflection and who had lymph node metasta-
sis in the mesorectum was 27%.
③ Urinary function and male sexual function may be 
impaired after lateral dissection, even if the autonomic 
nervous system is completely preserved.
[Aggregate data from the colorectal cancer registry]
① The incidence of lymph node metastasis according to 
site and depth of tumor invasion, curative resection 
rate, and 5-year survival rate are shown in Tables 6, 7, 
and 8 [29].
② The 5-year survival rates after curative resection of 
pStage 0 to pStage III colorectal cancer according to 
site were: All sites: 82.2%, Colon: 83.8%, Rectosig-
moid: 81.7%, Ra-Rb rectum: 79.3% (patients in years 
2000–2004).
Chapter 2: Treatment strategies for stage IV colorectal can-
cer [26] (Fig. 3)
•	 Stage IV colorectal cancer is associated with syn-
chronous distant metastasis to any of the following 
organs: liver, lung, peritoneum, brain, distant lymph 
nodes, or other organ (e.g., bone, adrenal gland, 
spleen).
•	 If both the distant metastases and the primary tumor 
are resectable, curative resection of the primary tumor 
is performed, and resection of the distant metastases is 
considered.
•	 If the distant metastases are resectable, but the primary 
tumor is unresectable, in principle, resection of the pri-
mary tumor and distant metastases is not performed, 
and another treatment method is selected.
•	 If the distant metastases are unresectable, but the pri-
mary tumor is resectable, the indication for the resection 
of the primary tumor is determined, based on the clini-
cal symptoms of the primary tumor and the impact on 
the prognosis (CQ-4).
Comments
① The incidence of synchronous distant metastasis is 
shown in Table 9.
② Distant metastasis associated with peritoneal dissem-
ination (CQ-6)
•	 Complete resection is desirable for P1.
•	 Complete resection is considered for P2 when eas-
ily resectable.
•	 The efficacy of resection of P3 has not been dem-
onstrated.
Fig. 3  Treatment strategies for 
Stage IV colorectal cancer Resection of synchronous 
distant metastases 
Resection of the 
primary tumor 
Resectable Unresectable 
Resectable Unresectable Resectable 
Symptoms caused by the primary tumor* 
Absent Present 
Resection of the 
primary tumor + 
metastatic tumor 
Treatment other than by 
resection for both the primary 
tumor and the metastatic tumor** 
Resection of the primary tumor + 
treatment other than resection for the 
metastatic tumor 
 * Symptoms caused by the primary tumor: Symptoms caused by events such as massive bleeding, severe 
   anemia, penetration / perforation, and stenosis. 
** Treatment other than by resection: Palliative surgery for the primary tumor, chemotherapy, radiotherapy;  
   see “treatment strategies for hematogenous metastasis”. 
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③ Cases accompanied by distant metastasis to multiple 
organs
•	 Typically, these cases involve metastasis to the 
liver or lungs.
•	 If it is safe and simple to remove the primary lesion 
and the metastasized lesions in the liver or lungs, 
resection should also be considered [35, 36]. (CQ-7)
④ Adjuvant therapy subsequent to the resection of dis-
tant metastasis
•	 The efficacy and safety of adjuvant chemother-
apy following the resection of distant metas-
tasis in colorectal cancer have not been estab-
lished, and no randomized controlled trials 
have been implemented regarding whether or 
not it extends survival [37, 38]. (CQ-8) Ideally, 
appropriately planned clinical trials should be 
implemented.
Chapter 3: Treatment strategies for recurrent colorectal 
cancer (Fig. 4)
•	 The goal of treatment for recurrent colorectal cancer 
is improvement of the prognosis and patient’s QOL.
•	 Treatment methods include surgery, systemic chemo-
therapy, arterial infusion chemotherapy, thermal coag-
ulation therapy, and radiotherapy.
•	 An appropriate treatment method is selected with the 
informed consent of the patient in view of a variety 
of factors, such as the prognosis, complications, and 
QOL expected after treatment.
•	 If recurrence is observed in a single organ and com-
plete surgical resection of the recurrent tumor(s) is 
possible, resection is strongly considered.
•	 If recurrence is observed in more than a single organ, 
resection can be considered if the recurrent tumors 
in all of the organs are resectable [35, 39]; however, 
Table 9  Incidence of 
synchronous distant metastasis 
of colorectal cancer
National registry of patients with cancer of the colon and rectum of the JSCCR: patients in years 2000–
2004
Liver Lung Peritoneum Other sites
Bone Brain Virchow Other Total
Colon cancer 11.8% 2.2% 5.7% 0.3% 0.0% 0.1% 1.3% 1.8%
No. of patients 15,391 1815 338 875 47 6 23 205 281
Rectal cancer 9.5% 2.7% 2.6% 0.5% 0.0% 0.1% 1.1% 1.7%
No. of patients 10,221 970 273 266 49 5 6 112 172
Total no. of patients 10.9% 2.4% 4.5% 0.4% 0.0% 0.1% 1.2% 1.8%
2785 611 1141 96 11 29 317 453
Fig. 4  Treatment strategies for 










In principle, surgical treatment is indicated for recurrence limited to 1 organ, but it 
is considered for recurrence in 2 or more organs, if the lesions are resectable. 
 * Local treatment includes hepatic arterial infusion therapy, thermal coagulation 
  therapy, and radiotherapy. 
** Best supportive care (BSC). 
***Recurrence may become resectable after successful chemotherapy. 
*** 
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there is no consensus on the effects of treatment (CQ-
7).
•	 Some authors believe that resection of liver or lung 
metastases should be performed only after a certain 
observation period to rule out occult metastases [40].
•	 Systemic chemotherapy is effective in regard to cases 
of inoperable liver metastasis, with some cases dem-
onstrating that curative resection may become possi-
ble [41, 42] (CQ-9).
•	 Treatment methods for hematogenous metastases (see 
chapter 4 “Treatment strategies for hematogenous 
metastases”)
•	 Local recurrences of rectal cancer take the form of 
anastomotic recurrences and intrapelvic recurrences.
(1) Resection is considered for resectable recur-
rences.
(2)  Radiotherapy and systemic chemotherapy, either 
alone or in combination, are considered for unre-
sectable recurrences.Comments
[Local recurrence of rectal cancer]
①. The extent of spread of the recurrent tumor is evalu-
ated by diagnostic imaging, and resection is considered 
only for patients in whom complete resection can be 
expected, after taking into consideration such factors as 
the pattern of recurrence, symptoms, and physical find-
ings (CQ-10).
Chapter 4: Treatment strategies for hematogenous metas-
tases (Fig. 5)
1. Treatment strategies for liver metastases
•	 Treatment of liver metastases is broadly divided into 
hepatectomy, systemic chemotherapy, hepatic arterial 
infusion therapy, and thermal coagulation therapy.
•	 Hepatectomy is recommended for liver metastases when 
curative resection is possible.
•	 Hepatectomy consists of systematic resection and par-
tial (non-systematic) resection.
•	 Indication criteria for hepatectomy
(1) The patient is capable of tolerating surgery
(2) The primary tumor has been controlled or can be 
controlled.
(3) The metastatic liver tumor can be completely 
resected.
(4) There are no extrahepatic metastases or they can 
be controlled.
(5) The function of the remaining liver will be ade-
quate.
•	 Systemic chemotherapy is considered for patients 
with unresectable liver metastases whose general 
condition can be maintained at a certain level or 
higher (PS 0 to PS 2).
•	 Thermal coagulation therapy consists of microwave 
coagulation therapy (MCT) and radiofrequency abla-
tion (RFA).
Fig. 5  Treatment strategies for 











 * Local treatment includes hepatic arterial infusion therapy, thermal coagulation 
  therapy, and radiotherapy. 
** Best supportive care (BSC). 
***Recurrence may become resectable after successful chemotherapy. 
*** 
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If the patient’s general condition is poor (PS ≥3), or 
there is no effective chemotherapy, best supportive care 
(BSC) is provided.Comments
[Hepatectomy]
① There are reports showing the efficacy of hepatectomy 
in patients who have controllable extrahepatic metasta-
ses (mainly lung metastases) in addition to liver metas-
tases [35, 36, 39, 43] (CQ-7).
② The efficacy of systemic chemotherapy and hepatic 
arterial infusion therapy after hepatectomy has not 
been established (CQ-8).
③ The safety of preoperative chemotherapy for resectable 
liver metastases has not been established (CQ-11).
[Treatment methods other than resection]
① Systemic chemotherapy is performed for patients with 
unresectable liver metastases (CQ-9).
② In cases of inoperable liver metastasis, the primary lesion 
should ideally be managed if hepatic arterial infusion 
therapy or heat coagulation therapy is being used (CQ-17, 
CQ-12).
③ Heat coagulation therapy is advantageous in that it is 
minimally invasive, in addition to having been reported 
as improving local control and long-term survival in 
some cases [44, 45]. However, there have not yet been 
any studies or reports of long-term prognosis involving 
sufficiently cumulative case studies; consequently, its 
efficacy has not been established. There is a high rate 
of recurrence in comparison to resection, however, and 
long-term survival is reported to be poor [46], so it is not 
recommended as an alternative to surgical resection [47] 
(CQ-12).
2. Treatment strategies for lung metastases
•	 Treatment of lung metastases consists of pneumonec-
tomy and systemic chemotherapy, and radiotherapy.
•	 Pneumonectomy is considered if the metastatic lung 
tumor is resectable.
•	 Pneumonectomy consists of systematic resection and 
partial (non-systematic) resection.
Indication criteria for pneumonectomy
(1) The patient is capable of tolerating surgery.
(2) The primary tumor has been controlled or can be 
controlled.
(3) The metastatic lung tumor can be completely 
resected.
(4) There are no extrapulmonary metastases or they 
can be controlled.
(5) The function of the remaining lung will be ade-
quate.
•	  Systemic chemotherapy is considered for patients 
with unresectable lung metastases whose general 
condition can be maintained at a certain level or 
higher.
•	  Even if the patient cannot tolerate surgery, stereo-
tactic body radiotherapy is considered if the pri-
mary tumor and extrapulmonary metastases are 
controlled or can be controlled and the number of 
lung metastases within 5 cm in diameter is no more 
than three [48].
•	  If the patient’s general condition is poor, appropri-
ate BSC is provided.
3. Treatment strategies for brain metastases
•	 Brain metastases are often detected as a part of a sys-
temic disease, and surgical therapy or radiotherapy 
is considered for lesions in which treatment can be 
expected to be effective.
•	 The optimal treatment method is selected after con-
sidering the patient’s general condition and status of 
other metastatic tumors, and evaluating the size and 
location of metastatic brain tumors and the number of 
brain lesions.
•	 Radiotherapy is considered for patients with unresect-
able metastases.
[Surgical therapy]
Indications criteria for brain resection [49]
(1) The patient has a life expectancy of at least several 
months.
(2) Resection will not cause significant neurologic symp-
toms.
(3) There are no metastases to other organs or they can be 
controlled.
[Radiotherapy]
•	 The purpose of radiotherapy is to relieve symptoms, 
such as cranial nerve symptoms and intracranial 
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hypertension symptoms, and to prolong survival time 
by reducing locoregional relapse.
•	 Whole-brain radiotherapy is considered for patients 
with multiple brain metastases and for patients with a 
solitary brain metastasis for which surgical resection 
is not indicated.
•	 Stereotactic irradiation is considered when the number 
of brain metastases is about no more than three or four 
and the maximum diameter of each metastasis does 
not exceed 3 cm.
4. Treatment strategies for hematogenous metastases to 
other organs
•	 Resection is also considered for other hematogenous 
metastases, such as to the adrenal glands, skin, and 
spleen, if they are resectable. However, patients with such 
metastases often have metastasis to more than one organ, 
and chemotherapy or radiotherapy is often indicated.
Chapter 5: Chemotherapy
•	 Chemotherapy consists of adjuvant chemotherapy to 
prevent postoperative recurrence and systemic chemo-
therapy to treat unresectable colorectal cancer.
•	 Commonly used anticancer drugs that have been 
approved for the indication of colorectal cancer and 
are covered by the Japanese National Health Insur-
ance include the following:
Oral drugs:  5-FU, tegafur, UFT, doxifluridine (5′-
DFUR), carmofur (HCFU), S-1 (S), 
UFT + leucovorin (LV), capecitabine 
(Cape), regorafenib, trifluridine–tipiracil 
hydrochloride (TAS-102), etc.
Injectable drugs:  5-FU, mitomycin C, irinotecan (IRI), 
5-FU + l-leucovorin (l-LV), oxalipl-
atin (OX), bevacizumab (Bmab), ramu-
cirumab (Rmab), cetuximab (Cmab), 
panitumumab (Pmab), etc.
1. Adjuvant chemotherapy
Chemotherapy Algorithm for unresectable, metasta	c colorectal cancer 
Pa	ents appropriate for intensive therapy Pa	ents not appropriate for intensive 
therapy 
*1  Combina	on with molecular target drugs such as Bmab, Rmab, 
an	-EGFR an	bodies, etc., is recommended, but for pa	ents who 
are not candidates, chemotherapy alone is carried out. 
*2 Indicated to RAS wild-type only. 
*3  Infusional 5-FU+l-LV 
*4  Refer to comment , ”2. Chemotherapy for unresectable 
colorectal cancer” , Chapter 5: Chemotherapy. 
*5  Combina	on with IRI is recommended for those who are 
candidates 
*6  Refer to comment , ”2. Chemotherapy for unresectable 
colorectal cancer” , Chapter 5: Chemotherapy. 
*7: Indicated for pa	ents above PS 2 or higher. 
*8: Refer to comment , ”2. Chemotherapy for unresectable 
colorectal cancer” , Chapter 5: Chemotherapy. 
Note: “/”, (slash) means select one of the listed regimens. 
Fig. 6  Chemotherapy for unresectable colorectal cancer
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•	 Postoperative adjuvant chemotherapy is a systemic 
chemotherapy that is performed after surgery to pre-
vent recurrence and improve the prognosis of patients 
who have undergone R0 resection [50].
General principles for the indications of adjuvant 
chemotherapy
(1) Stage III colorectal cancer (colon and rectal can-
cer) for which R0 resection has been performed. See 
CQ-8 for Stage IV resection cases.
(2) The function of major organs is maintained as pro-
vided by the following guidelines:
•	 Bone marrow: Peripheral blood neutrophil count 
>1500/mm3; platelet count >100,000/mm3
•	 Liver function: Total bilirubin <2.0 mg/dL; AST/
ALT <100 IU/L
•	 Renal function: Serum creatinine concentration is 
no higher than the upper limit of the normal range 
at the institution.
(3) Performance status (PS) of 0 or 1.
(4) The patient has recovered from postoperative compli-
cations, if any.
(5) The patient has provided written informed consent.
(6) The patient has no serious complications (particu-
larly intestinal obstruction, diarrhoea, or fever).
•	 For age, see CQ-13.
•	 For patients who have Stage II colorectal cancer 
with a high risk of recurrence, the indications for 
adjuvant chemotherapy are considered after obtain-
ing informed consent [51, 52] (CQ-14).
Recommended therapies (listed in the order of their date 
of coverage by the Japanese National Health Insurance)
•	 5-FU + l-LV (note)





Recommended administration period (CQ-15)
•	 In principle, the administration period is 6 months.
Note: The Roswell Park Memorial Institute (RPMI) 
method of 5-FU + LV therapy as adjuvant chemotherapy 
(drip infusion of l-LV 250 mg/m2 administered for 2 h; 
intravenous infusion of 5-FU 500 mg/m2 slowly adminis-
tered within 3 min at 1 h after initiating l-LV administra-
tion; and once weekly administration for six consecutive 
weeks followed by a 2-week rest period, three cycles every 
8 weeks [53]).
2. Chemotherapy for unresectable colorectal cancer (Fig. 6)
•	 In the best supportive care (BSC) without any chemo-
therapy, the median survival time (MST) of patients 
with unresectable colorectal cancer has been reported 
to be approximately 8 months. Although their MST has 
been extended to approximately 30 months because of 
recent chemotherapy, unresectable colorectal cancer 
remains difficult to cure.
•	 The purpose of chemotherapy is to prolong survival 
time and control symptoms by delaying tumour enlarge-
ment.
•	 Randomized controlled trials involving PS 0 to PS 2 
patients have shown that chemotherapy groups have a 
significantly longer survival time than BSC groups that 
did not receive anticancer drugs [54–56].
•	 Initially unresectable colorectal cancer may become 
resectable after successful chemotherapy.
•	 Patients should be ideally divided into two groups and 
their treatment policy selected according to whether or 
not they are appropriate for intensive therapy.
•	 Patients appropriate for intensive therapy include those 
with no serious comorbidities who are considered toler-
ant to primary treatment with OX and IRI, as well as 
concomitant therapy with molecular target drugs. These 
patients, who have considerably slow tumour advance-
ment and have preferably not suffered severe adverse 
events can be treated with either monotherapy or dou-
blet therapy as the primary treatment.
•	 Patients inappropriate for intensive therapy include 
those with serious comorbidities who are considered 
intolerant to primary treatment with OX and IRI, as well 
as concomitant therapy with molecular target drugs. For 
these patients, monotherapy or doublet therapy shall be 
considered as the primary treatment.
•	 Cmab and Pmab are only used in response to wild-type 
RAS(KRAS/NRAS).
•	 Combination with molecular target drugs, such as 
Bmab, anti-EGFR antibodies, or Rmab, is recom-
mended, but for patients who are not candidates, chem-
otherapy alone is administered.
General principles underlying the indications of systemic 
chemotherapy
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(1) The clinical or histopathological diagnosis has been 
confirmed.
(2) The metastatic or recurrent tumour can be confirmed 
by imaging.
(3) Performance status (PS) is 0–2.
(4) The function of major organs is maintained. (See 1–3 
below for administration guidelines).
1.  Bone marrow: Peripheral blood neutrophil count 
≧1500/mm3; platelet count ≧100,000/mm3
2.  Liver function: Total bilirubin <2.0 mg/dL; AST/
ALT <100 IU/L
3.  Renal function: Serum creatinine concentration is 
no higher than the upper limit of the normal range 
at the institution
(5) The patient has provided written informed consent.
(6) The patient has no serious complications (particularly 
intestinal obstruction, diarrhoea, or fever).
First-line therapy
•	 The following are regimens whose usefulness has been 
demonstrated in clinical trials. They are also available 
as the initial therapy covered by the Japanese National 
Health Insurance.
(1) Patients appropriate for intensive therapy
•	 FOLFOX (note 1) [57, 58] + Bmab [54]
•	 CapeOX (note 2) + Bmab [59, 60]
▪   SOX + Bmab (note 3) [61]
•	 FOLFIRI (note 4) [62, 63] + Bmab [64, 65]
•	 FOLFOX + Cmab/Pmab [66, 67]
•	 FOLFIRI + Cmab/Pmab [68, 69]
•	 FOLFOXIRI (note 5) [70]
▪   FOLFOXIRI + Bmab [71, 72]
•	 Infusional 5-FU + LV [73, 74] + Bmab [75, 76]
•	 Cape [77, 78] + Bmab [79]
•	 UFT + LV [80–82] + Bmab
▪   S-1 + Bmab
▪   Cmab/Pmab [83, 84]
(2) Patients not appropriate for intensive therapy
•	 Infusional 5-FU + LV + Bmab [75, 76]
•	 Cape + Bmab




•	 The following regimens are considered as chemother-
apy for second-line therapy (CQ-16).
(1) Patients appropriate for intensive therapy
(a) When the patient has become refractory or intolerant 
to the first-line therapy, including OX
•	 FOLFIRI [62] + Bmab [85]
▪   FOLFIRI + Rmab [86]
•	 IRIS (note 6) [87] + Bmab
•	 IRI [88] + Bmab
•	 FOLFIRI (or IRI) + Cmab/Pmab [88, 89]
(b) When the patient has become refractory or intolerant 
to the first-line therapy, including IRI
•	 FOLFOX [62, 90] + Bmab [85, 91]
•	 CapeOX (note 2) [92] + Bmab [85]
▪   SOX + Bmab
▪   FOLFOX + Cmab/Bmab
(c) When the patient has become refractory or intolerant 
to the first-line therapy, including 5-FU, OX, and IRI
•	 IRI + Cmab/Pmab [93]
•	 Cmab/Pmab [94–97]
2. Patients not appropriate for intensive therapy
•	 BSC
•	 If possible, consider the optimal regimen
Third-line and subsequent therapies
•	 The following regimens should be considered for 
their-line and subsequent therapies
•	 IRI + Cmab/Pmab [93]
•	 Cmab/Pmab [94–97]
•	 Regorafenib [98]
▪   TAS-102 [99, 100].
Comments
① Careful attention is required when using IRI to treat 
patients with constitutional jaundice, such as that 
caused by Gilbert’s syndrome, or those with high 
serum bilirubin values. Associations between genetic 
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polymorphisms of enzymes that metabolize IRI 
(UGT1A1) and toxicity have been suggested (see 
attached Side Memo 2).
② Although hepatic arterial infusion therapy shows high 
response rates for liver metastasis, it does not dem-
onstrate any survival benefit compared with systemic 
chemotherapy [101]. (CQ-17)
③ The efficacy and safety of Rmab are evaluated based 
on a RAISE study*, which has been approved for use 
in combination with 5-FU, l-LV, and IRI in Japan. In 
addition, as described in the drug package insert, the 
efficacy and safety have not been established in post-
operative adjuvant chemotherapy or the primary treat-
ment. We should also consider that the RAISE study 
has been performed only among patients with PS 0 or 
1, without evaluating the safety and efficacy in patients 
with PS 2–4.
④ The efficacy and safety of Regorafenib are evaluated 
on the basis of a CORRECT study [98]. As described 
in the drug package insert, the efficacy and safety have 
not been established in the primary or secondary treat-
ments. We should also consider that the safety and effi-
cacy have only been confirmed for patients with PS 0 
or 1, but not for those with PS 2–4.
⑤ The efficacy and safety of TAS-102 are evaluated on 
the basis of J-003 study and RECOURSE study. As 
described in the drug package insert, the efficacy and 
safety have not been established in the primary or sec-
ondary treatments [99, 100]. We should also consider 
that the RECOURSE study has been performed only 
among patients with PS 0 or 1, without evaluating the 
safety and efficacy in patients with PS 2–4.
⑥ MSI-high (microsatellite-instability-high) can be 
observed in patients with colorectal cancer hav-
ing Lynch syndrome caused by the mutations in 
the germlines of MMR (mismatch repair) genes or 
sporadic colorectal cancer caused by the acquired 
aberrant methylation of MLH1 genes. In general, 
it is found in approximately 5% of colorectal can-
cers [102]. Evidence for the effectiveness of chemo-
therapy only for MSI-high unresectable colorectal 
cancer has not been established, therefore under 
the current circumstances the common regimens for 
sporadic colorectal cancer are indicated for these 
patients. Some studies have recently reported that 
MSI-high may predict the poor prognosis of unre-
sectable colorectal cancer, along with the effects 
of anti-PD-1 antibodies [103], however anti-PD-1 
antibodies are not currently approved for MSI-high 
unresectable colorectal cancer in Japan. According 
to the NCCN guidelines as of February 2016, con-
ducting the MMR gene test and MSI test are rec-
ommended, as the screening for Lynch syndrome 
in colorectal cancer patients under the age of 70 as 
well as patients over 70 met Bethesda guidelines, 
and as a good prognosis factor and a predictor of 
the ineffectiveness of postoperative adjuvant 5-FU 
monotherapy for Stage II colon cancer [104]. In 
Japan, the MSI test is approved only for patients 
suspected of having Lynch syndrome, the diag-
nostic procedures of Lynch syndrome described in 
“JSCCR Guidelines 2016 for the Clinical Practice 
of Hereditary Colorectal Cancer.” [105].
Note 1:  FOLFOX—infusional 5-FU + LV + OX
Note 2:  CapeOX—Cape + OX
Note 3:  SOX—S-1 + OX
Note 4:  FOLFIRI—infusional 5-FU + LV + IRI
Note 5:  F O L F O X I R I — i n f u s i o n a l 
5-FU + LV + IRI + OX
Note 6:  IRIS—S-1 + IRI
Chapter 6: Radiotherapy
•	 Radiotherapy is used to treat patients with locally 
advanced rectal cancer either as adjuvant therapy 
after surgery to prevent recurrence or before surgery 
to reduce tumor volume and preserve the anal sphinc-
ter, and also as palliative care to relieve the symp-
toms and prolong the survival time of patients with 
unresectable colorectal cancer who have symptomatic 
lesions.
1. Adjuvant radiotherapy
•	 Adjuvant radiotherapy is classified into three catego-
ries, according to the timing of surgery and radiation 
therapy: preoperative radiotherapy, intraoperative 
radiotherapy, and postoperative radiotherapy.
•	 The purpose of adjuvant radiotherapy is to improve 
the local control rate and the survival rate of rectal 
cancer patients. The purpose of preoperative radio-
therapy includes improving the anal sphincter pres-
ervation rate and improving the resection rate. How-
ever, insufficient evidence of improved survival has 
been found to make this the objective of adjuvant 
radiotherapy.
•	 Preoperative radiotherapy is indicated for patients 
with T stage clinically diagnosed as “invasion depth 
cT3 (SS/A) or deeper or cN-positive”; postoperative 
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radiotherapy is indicated for patients with T stage 
pathologically diagnosed after surgery as “invasion 
depth cT3 (SS/A) or deeper or pN-positive, where 
the existence of a surgical dissection plane positive 
(RM1) or penetration of the surgical dissection plane 
by the cancer (RMX) is unclear”; and intraopera-
tive radiotherapy is indicated for “surgical dissection 
plane positive (RM1) or penetration of the surgical 
dissection plane by the cancer (RMX) is unclear”.
•	 Radiotherapy is delivered with a linear accelerator, 
where electron beams are used for intraoperative 
radiotherapy and photon beams for external radio-
therapy.
Comments
① Preoperative radiotherapy (CQ-18)
1. Preoperative radiotherapy has the following 
advantages: seeding during surgery can be pre-
vented by inactivating lesions with irradiation; 
a high percentage of tumor cells are normo-oxic 
and radiosensitive, because blood flow to the 
tumor is maintained; there has been little damage 
to the digestive tract, since the small bowel is not 
fixed within the pelvic cavity, thereby resulting 
in low radiation-induced delayed toxicity, which 
means a less toxic postoperative setting; improve-
ment in the R0 resection rate and anal sphincter 
preservation can be expected because of tumor 
size reduction [106].
2. Preoperative radiotherapy has the following dis-
advantages: early-stage patients may be subjected 
to overtreatment and postoperative complications 
may increase.
3. Twelve phase III clinical trials of preoperative 
radiotherapy (without chemotherapy) have been 
reported [106], and in five of the 12 randomized 
controlled trials the local control rate in the group 
that received preoperative radiotherapy was sig-
nificantly higher than in the surgery alone group. 
However, an improvement in the survival rate was 
observed in only one trial [107].
4. Two meta-analyses of radiotherapy showed 
improvement in the local control rate compared 
to surgery alone, and improvement in the survival 
rate in the groups that received doses of 30 Gy or 
more. However, there is controversy as to whether 
there is improvement in the survival rate [108, 
109].
 5 Gy per fraction have been conducted, mainly in 
Europe [107, 110]. Because the late effects of 
radiation depend on the fraction size, long-term 
follow-up for late adverse effects, such as anal 
dysfunction and bowel dysfunction, is necessary.
6. In the Dutch CKVO 95-04 trial, which compared 
preoperative radiotherapy (25 Gy delivered in five 
fractions in one week) + TME and TME alone 
to investigate the significance of adding short-
course radiotherapy to TME, the 5- and 10-year 
local control rates were significantly higher in 
the combination therapy group, but there was no 
significant difference between the two groups in 
the 5- and 10-year survival rates [110–112]. The 
incidences of sexual dysfunction and bowel dys-
function were higher in the preoperative radiation 
combination therapy group than in the surgery-
alone group [113, 114].
7. The effect of preoperative radiotherapy in reduc-
ing the size of the primary tumor may enable 
sphincter preservation. When the purpose of the 
preoperative radiotherapy is sphincter preser-
vation, it is desirable to perform surgery after 
allowing an appropriate period for the tumor to 
decrease in size (6–8 weeks after the completion 
of radiotherapy) [115].
8. In Europe, four randomized controlled trials, 
including the EORTC trial, were performed to 
investigate the usefulness of adding chemother-
apy to preoperative radiotherapy. The incidence 
of acute-phase adverse events was significantly 
higher in the preoperative chemoradiotherapy 
groups, but the pathologic complete response 
rates (pCR) were significantly higher than in the 
preoperative radiotherapy alone groups. In two 
trials, the exception being the short-course radio-
therapy trial, the local recurrence rate was signifi-
cantly lower in the preoperative chemoradiother-
apy group, and there was no significant difference 
between the two groups in terms of sphincter 
preservation or survival rate [111–118].
9. In a randomized controlled trial that compared 
preoperative chemoradiotherapy and postopera-
tive chemoradiotherapy, there was no significant 
difference in the 5-year survival rate, but the local 
recurrence rate and incidence of grade 3 or higher 
adverse events were significantly lower in the 
preoperative chemoradiotherapy group. Among 
the patients in whom abdominoperineal resec-
tion (APR) was considered necessary at the time 
of enrollment, the percentage of patients in whom 
sphincter preservation was possible was signifi-
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cantly higher in the preoperative chemoradiother-
apy group [119].
10. A randomized controlled trial of 5-FU versus 
Cape combination chemotherapy in the preop-
erative chemoradiotherapy indicated that the 
two drugs had the same level of efficacy and 
safety [120, 121]. NCCN Guidelines allow the 
use of either 5-FU or Cape as standard combina-
tion chemotherapy in the preoperative chemora-
diotherapy. The indications and use of Cape as 
an adjuvant therapy for rectal cancer has been 
approved for use under health insurance in Japan 
as of August 2016.
11. In randomized controlled trials into the efficacy 
of adding OX to pyrimidine fluoride as a combi-
nation chemotherapy in the preoperative chemo-
radiotherapy, OX increased harmful phenomena 
in three tests, but demonstrated no efficacy in 
regard to pCR ratio, localized control ratio and 
survival [120, 122–124]; moreover, in one test, 
although there was no difference in harmful phe-
nomena and no analysis was done into disease-
free survival at the primary endpoint, the pCR 
ratio was significantly higher [125].
2. Palliative radiotherapy
(a) Intrapelvic lesions (CQ-19)
•	 The purpose of palliative radiotherapy for 
intrapelvic lesions is to relieve symptoms such 
as pain, hemorrhage, and bowel movement dis-
orders caused by intrapelvic tumors.
•	 The target volume includes the tumor that is 
causing the symptoms.
[Dose and fractionation]
•	 A total dose of 45 Gy to 50 Gy is administered in 1.8–
2.0 Gy fractions.
•	 Depending on the patient’s general condition, such as 
performance status, and the severity of the symptoms, 
radiotherapy may be completed in a shorter term with 
a larger fraction size, for example 30 Gy in 10 frac-
tions over 2 weeks.
(b) Extrapelvic lesions
(1) Bone metastases
•	 The purpose of palliative radiotherapy for bone 
metastases is to achieve pain relief, prevent 
pathological fractures, and prevent and treat 
spinal cord paralysis.
•	 The target volume includes the metastatic bone 
lesions causing the symptoms.
[Dose and fractionation]
•	 Local field radiotherapy, such as 30 Gy in 10 fractions 
and 20 Gy in five fractions, is widely performed.
(2) Brain metastases
•	 See the section on hematogenous metastases 
(Chapter 4).
[Dose and fractionation]
•	 When whole brain radiotherapy is performed, 30 Gy 
in 10 fractions is the standard treatment. If long-term 
survival is expected, fractionated radiotherapy, such as 
37.5 Gy in 15 fractions and 40 Gy in 20 fractions, is 
considered.
•	 When stereotactic radiosurgery is performed, a 
peripheral dose of 16 Gy to 25 Gy is delivered in a 
single fraction.
Chapter 7: Palliative care
•	 Palliative care is a general term for palliative treat-
ment of various mental and physical symptoms related 
to cancer.
•	 Palliative care extends from the time the diagnosis 
of cancer is made to the end stage, and different care 
should be provided depending on the disease stage 
and symptoms.
•	 In principle, cancer treatment should be performed 
under conditions in which symptom relief is 
achieved [126], and palliative care should be started 
at the same time as surgical treatment and chemo-
therapy.
•	 Palliative care to improve the QOL of patients with 





5. Counseling for psychiatric symptoms
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Chapter 8: Surveillance after surgery for colorectal 
cancer
1. Surveillance for recurrence after curability A resection 
of colorectal cancer
(1) Consideration should be given to periodic endoscopic 
examination for recurrence at the site of local resection 
or anastomosis in pStage 0 [pTis (M) cancer] cases. 
Surveillance for recurrence in other organs is not nec-
essary.
(2) pStage I–pStage III cases should be surveyed for recur-
rence in the liver, lungs, local area, anastomosis, lymph 
nodes, peritoneum, etc. The following points should be 
noted.
•	 In principle, the duration of surveillance is 5 years 
after surgery, but the surveillance examinations 
should be scheduled at shorter intervals during the 
first 3 years after surgery.
•	 It should be noted that there is a higher incidence of 
lung metastasis and local recurrence in rectal cancer 
than in colon cancer.
•	 As a general rule, the duration of surveillance for 
anastomotic recurrence is until 3 years after surgery.
•	 The following is an example of a surveillance sched-
ule after curative resection of Stage I to Stage III 
colorectal cancer that was designed on the basis of 
the results of a retrospective investigation of such 
factors as the common sites and incidence of recur-
rence and the efficacy of treatment and the clinical 
practice in Japan (Fig. 7).
2. Surveillance after curability B resection of colorectal 
cancer and after resection of recurrent tumors.
(1) The same surveillance method as for Stage III 
colorectal cancer is used. It should be noted that 
recurrence and re-recurrence are common in 
organs previously operated on.
(2) In cases allocated curability B due to R1 resec-
tion, close surveillance schedule should be 
planned for organs in which residual cancer is 
suspected.
3. Surveillance of metachronous multiple cancer
•	 Colonoscopy is performed for surveillance of 
metachronous multicentric colorectal cancer.
Fig. 7  An example of a surveil-
lance schedule after curative 
resection of pStage I to pStage 
III colorectal cancer
Years/months after surgery 1 year 2 years 3 years 4 years 5 years 
3m 6 9 12 3 6 9 12 3 6 9 12 3 6 9 12 3 6 9 12 















Abdominal and  
pelvic CT 
Colonoscopy 
: Performed for Stage I to Stage III colorectal cancer. 
: Performed for Stage III colorectal cancer. Can be omitted in Stage I and Stage II colorectal cancer. 
Diagnostic imaging of the chest: CT is desirable, but plain chest X-ray is acceptable. 
Diagnostic imaging of the abdomen: CT is desirable, but abdominal ultrasound is acceptable. 
(Years after surgery) 
Stage I 1367 patients 
Stage II 1912 patients 
Stage III 1951 patients 


























Fig. 8  Graph of the cumulative incidence of recurrence according to 
stage (project study by the JSCCR: patients in years 1991–1996)
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Comments
① Aim of surveillance
•	 The aim of surveillance is to improve the patient’s 
prognosis by early detection and treatment of 
recurrences. Meta-analyses of RCTs conducted in 
Europe and the United States have shown that sur-
veillance after curative surgical resection of colo-
rectal cancer contributes to improving the resection 
rate of recurrent tumors and to improving the prog-
nosis [127–131] (CQ-20-1).
② Recurrence rate, sites of recurrence, times of recur-
rence
•	 The results of the project study by the JSCCR are 
shown in Figs. 8, 9 and Tables 10, 11, 12, and 13. 
The subjects were patients who underwent curative 
resection of colorectal cancer between 1991 and 
1996 at the 14 institutions that participated in the 
project, and the follow-up period was 6–11 years.
(1) Times of the recurrences and sites of the recurrences 
(Fig. 9, Tables 10, 12, 13).
•	 More than 80% of the recurrences were detected 
within 3 years after surgery, and more than 95% of 
the recurrences were detected within 5 years after 
surgery.
Fig. 9  Graph of the cumulative 
incidence of recurrence accord-
ing to the site of recurrence 
(project study by the JSCCR: 
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Local recurrence 209 patients 
Anastomotic recurrence 22 
patients 
Table 10  Recurrence rate after curative resection of colorectal cancer according to stage and cumulative incidence of recurrence according to 
the number of years after surgery
Project study of the JSCCR: patients in years 1991–1996
Stage (no. of patients) Recurrence rate (no. 
of patients with recur-
rence)
Cumulative incidence of recurrence according to the no. 
of years after surgery (cumulative no. of patients with 
recurrence)
Percentage of patients experienc-
ing recurrence more than 5 years 
after surgery among all patients 
(no. of patients)
3 years 4 years 5 years
I 3.7% 68.6% 82.4% 96.1% 0.15%
(1367) (51) (35) (42) (49) (2)
II 13.3% 76.9% 88.2% 92.9% 0.94%
(1912) (255) (196) (225) (237) (18)
III 30.8% 87.0% 93.8% 97.8% 0.67%
(1957) (600) (522) (563) (587) (13)
All 17.3% 83.2% 91.6% 96.4% 0.63%
(5230) (906) (753) (830) (873) (33)
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•	 The overall incidence of recurrence more than 
5 years after surgery was less than 1%.
•	 Among lung recurrences, 5% of recurrences were 
detected more than 5 years after surgery.
•	 More than 95% of the anastomotic recurrences 
were detected within 3 years after surgery.
•	 Local recurrence and lung recurrence were more 
frequent in rectal cancer than in colon cancer.
•	 There have been reports regarding recurrences 
after curative resection in Europe and the United 
States showing that approximately 50% of the 
recurrences were detected within 1 year after sur-
Table 11  Recurrence rate of 
Stage I colorectal cancer (RS 
cancer was counted as colon 
cancer)
Project study of the JSCCR: patients in years 1991–1996
Stage I No. of patients No. of patients with recurrence Recurrence rate (%) p value
Tumor location
 Colon 891 24 2.7 0.0056
 Rectum 476 27 5.7
Depth of tumor invasion
 SM 714 9 1.3  <0.0001
 MP 653 42 6.4
Tumor location and depth of tumor invasion
 Colon
  SM 528 7 1.3  0.0024
  MP 363 17 4.7
 Rectum
  SM 186 2 1.1  0.0005
  MP 290 25 8.6
Table 12  Recurrence rate according to the site of the first recurrence after curative resection of colorectal cancer and cumulative incidence of 
recurrence according to the number of years after surgery
Project study of the JSCCR: patients in years 1991–1996
Site of first recurrence Recurrence rate (no. of 
patients with recurrence 
(including overlaps)
Cumulative incidence of recurrence according to 
the number of years after surgery (cumulative no. of 
patients with recurrence)
Percentage of patients experiencing 
recurrence more than 5 years after 
surgery among all patients (no. of 
patients)
3 years 4 years 5 years
Liver 7.1% (373) 87.9% (328) 94.1% (351) 98.7% (368) 0.10% (5)
Lung 4.8% (250) 78.0% (195) 88.8% (222) 94.8% (237) 0.25% (13)
Local 4.0% (209) 80.9% (169) 90.4% (189) 96.2% (201) 0.15% (8)
Anastomotic 0.4% (22) 95.5% (21) 95.5% (21) 95.5% (21) 0.02% (1)
Other 3.8% (199) 79.4% (158) 91.0% (181) 95.5% (190) 0.17% (9)
All (5230) 17.3% (906)
Table 13  Comparison between 
the recurrence rates of colon 
cancer and rectal cancer 
according to the site of the first 
recurrence (RS cancer was 
counted as colon cancer)
Project study of the JSCCR: patients in years 1991–1996
Site of recurrence Colon cancer (3583 patients) Rectal cancer (1647 patients) p value
Liver 7.0% (252) 7.3% (121) NS
Lung 3.5% (126) 7.5% (124) <0.0001
Local 1.8% (64) 8.8% (145) 0.0001
Anastomotic 0.3% (9) 0.8% (13) 0.0052
Other 3.6% (130) 4.2% (69) NS
All 14.1% (506) 24.3% (400) <0.0001
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gery, that approximately 70% of the recurrences 
were detected within 2 years after surgery [132, 
133]; and that in most patients the recurrences 
were detected within 5 years after surgery [133].
(2) Characteristics of recurrence according to pStage 
(Fig. 8, Tables 10, 11)
1. pStage I
•	 The recurrence rate of pT1 (SM) cancer was approx-
imately 1% in both colon cancer and rectal cancer.
•	 The overall recurrence rate of pT2 (MP) cancer was 
6.4%, and it was 5.0% in colon cancer and 8.3% in 
rectal cancer.
•	 Two-thirds of the recurrences were detected 
within 3 years after surgery, and the overall inci-
dence of recurrence more than 5 years after sur-
gery was less than 0.2% among all patients.
2. pStage II, pStage IIIa, and pStage IIIb
•	 The recurrence rate increased with the Stage.
•	 78–90% of recurrences were detected within 
3 years after surgery, and the overall incidence of 
recurrence more than 5 years after surgery was less 
than 1% among all patients.
③ Surveillance of metachronous multiple primary cancer
•	 A past history of colorectal cancer, regardless of stage, 
is a risk factor for metachronous colorectal cancer [134].
•	 The recommended interval between colonoscopy 
ranged from 1 to 5 years, depending on the report 
[135].
•	 The need for surveillance targeting multiple cancers 
should be determined by distinguishing hereditary 
colorectal cancer [105]. There is little evidence of a 
need for periodic minute examinations for cancer in 
other organs following surgery for sporadic colorec-
tal cancer (CQ-20-2).
Clinical questions
CQ-1: What are the indication criteria for additional 
treatment after endoscopic resection of pT1 (SM) [26]? 
(Fig. 10)
① Surgical resection is preferable when the vertical mar-
gin is positive (recommendation/evidence level 1C).
② If any of the following findings is observed during his-
tological examination of the resected specimen, intesti-
nal resection with lymph node dissection is considered 
as an additional treatment (evidence level B).
(1) Depth of SM invasion ≥1000 µm
(2) Vascular invasion positive
(3) Poorly differentiated adenocarcinoma, signet-ring 
cell carcinoma, or mucinous carcinoma [136]
(4) Grade 2/3 budding at the site of deepest invasion 
[136]
Note
•	 “Vertical margin-positive” means that carcinoma is 
exposed at the submucosal margin of the resected 
specimen.
Fig. 10  Treatment strategies 
for pT1 (SM) cancer after endo-
scopic resection
Negative vertical margin Positive vertical margin 
Depth of invasion 
≥1000 µm 








Intestinal resection with lymph node dissection 
is considered 
Intestinal resection with 
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Fig. 11  Method for measur-
ing depth of SM invasion. a 
When it is possible to identify 
or estimate the location of the 
muscularis mucosae, depth 
of SM invasion is measured 
from the lower border of the 
muscularis mucosae. b, c When 
it is not possible to identify 
or estimate the location of the 
muscularis mucosae, depth of 
SM invasion is measured from 
the surface layer of the mus-
cularis mucosae. Sessile lesion 
(b), Pedunculated lesion (c). d 
For pedunculated lesions with 
tangled a muscularis mucosae, 
depth of SM invasion is meas-
ured as the distance between 
the point of deepest invasion 
and the reference line, which 
is defined as the boundary 
between the tumor head and the 
stalk. e Invasion by peduncu-
lated lesions that is limited to 
within the head is defined as 
“head invasion”
Fig. 12  Venous invasion (arrow 
in A). A Located in the vicinity 
of an artery (a). B Elastic fibers 
in the vein wall have become 
clear by Victoria blue staining
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•	 Depth of SM invasion is measured by the method 
described in Side Memo 1 (Fig. 11).
•	 Vascular invasion consists of lymphatic and venous 
invasion (Figs. 12, 13, 14).
•	 The method of assessing budding is described in 
Fig. 15.
The principle for treatment of pT1 (SM) carcinomas, 
which are invasive carcinomas, is intestinal resection with 
lymph node dissection. However, some pT1 (SM) car-
cinomas have a very low risk of metastasis, and the pur-
pose of these criteria is to minimize the need for additional 
resections that eventually result in overtreatment of such 
patients. While no diagnostic methods make it possible to 
predict lymph node metastasis (pN) without fail, the degree 
of risk of metastasis can be used as a basis for determining 
whether or not to perform additional treatment.
Factors such as the depth of submucosal invasion (SM 
invasion depth) [137], histological type, such as poorly dif-
ferentiated adenocarcinoma, signet-ring cell carcinoma, 
and mucinous carcinoma [136], the presence of a poorly-
differentiated area and muconodules at the site of deep-
est invasion, budding, and vascular invasion, have been 
reported to be risk factors for regional lymph node metasta-
sis by pT1 (SM) carcinoma [136, 137].
The above criteria for determining whether addi-
tional treatment is indicated were prepared based on 
the following three criteria for performing additional 
Fig. 13  Lymphatic invasion 
(arrow in a). a A cancer cell 
nest is visible in the interstitial 
space. b Double staining for 
cytokeratin and D2-40. Cancer 
cells are stained brown, and 
the lymphatic endothelium is 
stained purplish red
Fig. 14  Space formed by 
artifacts during preparation of 
the specimen (arrow in a). a 
A cancer cell nest is visible in 
the interstitial space. b Double 
staining for cytokeratin and 
D2-40. The interstitial space is 
D2-40-negative
Fig. 15  Budding (arrow in b). 
A cancer cell nest consisting of 
one or fewer than five cells that 
has infiltrated the interstitium 
at the invasive margin of the 
cancer is seen. b is the square 
area in a
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intestinal resection of pT1 (SM) carcinoma described in 
the “Japanese Classification of Colorectal Carcinoma” 
(2nd edition, 1980): [(1) Obvious intravascular carci-
noma invasion; (2) Poorly differentiated adenocarcinoma 
or undifferentiated carcinoma; (3) Massive carcinoma 
invasion extending to the vicinity of the margin] [138]. 
The description of “Massive carcinoma invasion” in the 
4th edition of the “Japanese Classification of Colorectal 
Carcinoma” was revised to the following more specific 
description in the 5th edition (1994): “Invasion deeper 
than ‘very shallow invasion’ (e.g., invasion exceeding 
approximately 200–300 μm)” [139].
Subsequent case series studies in Japan have shown 
that “200–300 μm” can be extended to 1000 μm [140]. 
According to the results of the project study by the 
JSCCR, the lymph node metastasis rate of colorectal car-
cinoma with an SM invasion depth of 1000 μm or more 
was 12.5% (Table 14) [137, 140]. However, not all cases 
with submucosal invasion deeper than 1000 μm neces-
sarily require additional surgery. Approximately 90% of 
patients with a depth of invasion of 1000 μm or more 
did not have lymph node metastasis, and it is important 
to determine whether additional treatment is indicated 
after sufficiently considering other factors in addition to 
depth of SM invasion, such as whether other risk factors 
for lymph node metastasis are present, the physical and 
social background of the patient, and the patient’s wishes. 
As consensus has not yet been achieved within the 
Guideline Committee, indicators of strength of recom-
mendation in the treatment criteria provided above have 
not been disclosed. Because budding was demonstrated 
to be an important risk factor for lymph node metastases 
in the project study by the JSCCR, additional intestinal 
resection has been added to the list of factors that should 
be considered in the previous edition. Furthermore, pro-
ject research is currently underway into other histopatho-
logical factors. Multi-center joint research projects have 
produced reports providing the results of consideration 
into the appropriateness of these criteria [141–143]. None 
of the guidelines in other countries include depth of inva-
sion or budding as criteria for additional treatment.
CQ-2: What are the criteria for selecting endoscopic resection in 
regard to lesions with a maximum diameter of 2 cm or greater?
•	 Accurate preoperative endoscopic diagnosis is essential 
in endoscopic resection in regard to lesions with a maxi-
mum diameter of 2 cm or greater, and whether resection 
by EMR, piecemeal EMR, or ESD is indicated is deter-
mined after taking the operator’s skill in performing 
endoscopic resection into consideration. (Recommenda-
tion/Evidence level 1B)
Side Memo 1
▪    Method for measuring depth of SM invasion (Fig. 11) 
When it is possible to identify or estimate the loca-
tion of the muscularis mucosae, depth of SM invasion 
is measured from the lower border of the muscularis 
mucosae of the lesion, regardless of the macroscopic 
type.
•	 When it is not possible to identify or estimate the loca-
tion of the muscularis mucosae, the depth of SM inva-
sion is measured from the surface of the lesion. The 
phrase “possible to identify or to estimate” means that 
there is no “deformity”, i.e., disarray, dissection, rup-
ture, fragmentation, etc., of the muscularis mucosae 
as a result of SM invasion. If a deformed muscularis 
mucosa is used as the base line of the measurement, the 
depth of SM invasion may be underestimated. Although 
judging whether there is a “deformity” is not always 
straightforward, if a desmoplastic reaction is present 
around the muscularis mucosae, it is assumed to be 
“deformed.”
Table 14  Depth of invasion 
of sm cancer and lymph node 
metastasis (modified from 
Reference 201)
The lymph node metastasis rate of patients with a depth of invasion of 1000 μm or above was 12.5%
All three lymph node metastasis-positive patients with head invasion were ly positive
sm invasion distance (μm) Pedunculated Non-pedunculated
Number of lesions n (+) (%) Number of lesions n (+) (%)
head invasion 53 3 (5.7)
0 < X<500 10 0 (0) 65 0 (0)
500 ≤ X < 1000 7 0 (0) 58 0 (0)
1000 ≤ X < 1500 11 1 (9.1) 52 6 (11.5)
1500 ≤ X < 2000 7 1 (14.3) 82 10 (12.2)
2000 ≤ X < 2500 10 1 (10.0) 84 13 (15.5)
2500 ≤ X < 3000 4 0 (0) 71 8 (11.3)
3000 ≤ X < 3500 9 2 (22.2) 72 5 (6.9)
3500 ≤ X 30 2 (6.7) 240 35 (14.6)
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•	 For pedunculated lesions with a tangled muscularis 
mucosae, depth of SM invasion is measured as the dis-
tance between the point of deepest invasion and the ref-
erence line, which is defined as the boundary between 
the tumor head and the stalk (the boundary between the 
tumor area and the non-tumor area in the mucosa). Inva-
sion by pedunculated lesions that is limited to within the 
head is defined as “head invasion.”
▪    Method for assessing vascular invasion (Figs. 12, 13, 
14)
•	 Attention to arteries is a key factor in assessing venous 
invasion. Venous invasion is highly likely when a circu-
lar, semicircular, or oblong cancer cell nest with regular 
margins is located in the vicinity of an artery and dis-
tant from the main lesion. If such a cancer cell nest is 
surrounded by venous wall structures (such as internal 
elastic membrane or perivascular smooth muscle), it can 
be concluded to represent venous invasion. However, 
the venous wall structures are often displaced or oblit-
erated by the cancer cell nest, and it is difficult to recog-
nize in hematoxylin and eosin stained sections.
•	 The presence of cancer cells and cancer cell nests in the 
interstitial space suggests lymphatic invasion. A space 
filled with lymph and lymphocytes is especially likely 
to be a lymph vessel. When endothelial cells are iden-
tified around the space, the space can be concluded to 
represent a lymph vessel. However, it is often difficult 
to identify endothelial cells in specimens stained with 
hematoxylin and eosin, and spaces may be artifacts cre-
ated during the process of preparing the specimen.
•	 As stated above, evaluation of vascular invasion, which is 
an important indicator for determining treatment strategies 
for SM cancer, is often difficult in hematoxylin and eosin 
stained specimens. Special staining methods are useful for 
evaluating vascular invasion, such as elastica van Gieson 
staining or Victoria blue staining for venous invasion, and 
D2-40 immunostaining for lymphatic invasion.
▪   Method for the assessing tumor budding (Fig. 15)
[Definition of tumor budding] [136] A cancer cell nest 
consisting of one or fewer than five cells that infiltrates the 
interstitium at the invasive margin of the cancer.
[Grade of budding] After selecting one field where bud-
ding is the most intensive, number of buddings is counted in 
a field measuring 0.785 mm2 observed through a 20× objec-
tive lens (WHK 10× ocular lens). Depending on the number 
of buddings, Grade of budding is defined as follows:
Grade 1:  0–4
Grade 2:  5–9
Grade 3:  10 or more
•	 The lymph node metastasis rate by Grade 2/3 tumors 
is significantly higher than by Grade 1 tumors. A 
multi-center study conducted by the Budding Inves-
tigation Project Committee (2005–) of the JSCCR 
in which Grade 1 was defined as “low grade” and 
Grade 2/3 as “high grade” showed that “high grade” 
is an independent predictor of lymph node metasta-
sis.
CQ-3: what cautions should be noted when using colorectal 
ESD to implement endoscopic resection of colonic lesions?
•	 While ESD is used in cases of “early-stage malig-
nant tumors,” accurate preoperative endoscopic diag-
nosis and the level of skill of the operator in regard 
to endoscopic resection should be considered before 
deciding to proceed. (Recommendation/Evidence 
level 1B)
CQ-4: is laparoscopic surgery for colorectal cancer 
effective?
•	 According to randomized controlled trials held 
overseas and the Cochrane Database of Systematic 
Reviews, the safety and long-term outcome of lapa-
roscopic surgery in cases of colonic and RS cancers 
are similar to those in open surgery. As D3 dissec-
tion is difficult under laparoscopic conditions, lapa-
roscopic surgery for cStage II–cStage III disease 
should be implemented when it is considered that 
the individual surgical team is sufficiently expe-
rienced. Laparoscopic surgery is also difficult in 
patients with transverse colon cancer, in severely 
obese patients, and in patients with severe adhe-
sions.
•	 The efficacy and safety of laparoscopic surgery for 
rectal cancer has not been established. Ideally, appro-
priately planned clinical trials should be implemented. 
(Recommendation/Evidence level 1B).
CQ-5: resection of the primary tumor in patients with 
unresectable distant metastases
•	 The efficacy of primary tumor resection in cases with 
unresectable distant metastasis differs depending on 
individual factors such as symptoms caused by the 
primary lesion, the state of distant metastasis, the 
patient’s general condition, etc.
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① If symptoms exist as a result of the primary tumor, 
which are difficult to control using other therapies, 
and the resection is not significantly invasive, primary 
tumor resection and early systemic chemotherapy is 
recommended. (Recommendation/Evidence level 1C)
② For cases in which no symptoms are caused by the pri-
mary tumor; however, the efficacy of resecting the pri-
mary tumor has not been established.
CQ-6: in cases where peritoneal dissemination is noted, is 
it effective to resect peritoneal dissemination at the same 
time as the primary lesion?
•	 The efficacy of resecting peritoneal dissemination has 
not been proven. Some cases of long-term survival 
have been reported in which localized dissemination 
(P1, P2) was resected alongside the primary tumor, 
suggesting that if the resection is not significantly 
invasive, then the peritoneal dissemination should be 
resected at the same time as the primary tumor (rec-
ommendation/evidence level 2D).
CQ-7: what are the indications for resection for cases in 
which metastasis is simultaneously noted in the liver and 
the lungs?
•	 The efficacy of resection in patients who have liver 
and lung metastases at the same time has been shown, 
and thus resection should be considered for patients 
with resectable liver and lung metastases.
However, there are insufficient data to determine the 
indication criteria for surgery. It is necessary to obtain 
informed consent after informing the patient of the rather 
low cure rate and the absence of outcome predictors (rec-
ommendation/evidence level 2D).
CQ-8: is adjuvant chemotherapy effective subsequent to 
distant metastatic lesion resection?
•	 The efficacy and safety of adjuvant chemotherapy sub-
sequent to distant metastatic lesion resection in cases 
of colorectal cancer have not yet been established. 
Ideally, appropriately planned clinical trials should be 
implemented. (Evidence level C)
CQ-9: is resection of liver/lung metastasis effec-
tive, if it becomes possible as a result of the effects of 
chemotherapy?
•	 Resection should be performed for cases in which 
chemotherapy has successfully made localized metasta-
sis to the liver or lungs operable (recommendation/evi-
dence level 2D).
CQ-10: what are the surgical indications in cases of local 
recurrence of rectal cancer?
•	 Resection should be considered for local recurrence of 
rectal cancer when R0 resection is considered possible 
(recommendation/evidence level 2D).
CQ-11: is preoperative adjuvant chemotherapy effective in 
cases of operable liver metastasis?
•	 The efficacy and safety of preoperative chemotherapy 
for resectable liver metastases has not been established. 
It should be evaluated in properly designed clinical tri-
als (evidence level D).
CQ-12: is heat coagulation therapy effective in regard to 
liver metastatic lesions?
① There are few reports indicating the efficacy of heat 
coagulation therapy, and as such, it is not recom-
mended as a first choice of treatment (recommenda-
tion/evidence level 1C).
② Since heat coagulation therapy is accompanied by a 
high risk of local recurrence in cases of liver metasta-
sis, resection should be initially considered wherever 
possible.
CQ-13: is postoperative adjuvant chemotherapy effective 
in patients aged 70 or over?
•	 Even in patients 70 years old or older, postoperative 
adjuvant chemotherapy is recommended if their PS is 
good, if the function of major organs is adequate, and 
if there are no complications that may be a risk for 
performing chemotherapy (recommendation/evidence 
level 1A).
CQ-14: should postoperative adjuvant chemotherapy for 
Stage II [26] colorectal cancer be carried out?
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•	 The usefulness of postoperative adjuvant chemother-
apy for Stage II colorectal cancer has not been proven, 
and it is recommended not to routinely administer 
adjuvant chemotherapy to all patients with Stage II 
colorectal cancer (recommendation/evidence level 
1A).
CQ-15: is the appropriate duration of postoperative adju-
vant chemotherapy six months?
•	 Although no definitive conclusion regarding the dura-
tion of postoperative adjuvant chemotherapy has been 
reached, the current standard duration of treatment by 
5-FU-based adjuvant chemotherapy is 6 months (rec-
ommendation/evidence level 1A).
CQ-16-1: is concomitant therapy with molecular target 
drugs recommended as the primary treatment?
As long as there are no contraindications, usage in com-
bination with bevacizumab, cetuximab or panitumumab is 
recommended (recommendation level/evidence level 1A).
CQ-16-2: is concomitant therapy with molecular target 
drugs recommended as the secondary treatment?
As long as there are no contraindications, consider a com-
bination of the following molecular target drugs as the sec-
ondary treatment.
Bmab: Proposed regardless of the primary treatment 
regimen (2B),
Anti-EGFR antibody drugs: Not recommended for 
patients treated with anti-EGFR antibody in the primary 
treatment (1D),
Proposed for the patients treated without anti-EGFR 
antibody in the primary treatment (2C).
CQ16-3: is of regorafenib or TAS-102 therapy recom-
mended for 3rd or later line treatment?
Propose both drugs for patients with PS0-1 who are failed 
or intolerant to the standard therapy. (1A)
Side Memo 2
▪   IRI and UGT1A1 genetic polymorphism
SN-38 is an active metabolite of IRI and the UGT1A1 
gene encodes an intrahepatic metabolizing enzyme, 
which converts the active form SN-38 to the inactive 
form SN-38 G. In patients who are double heterozygotes 
for *6 and *28 or homozygotes for *6 or *28 of the 
UGT1A1 gene, the glucuronic acid conjugation capacity 
of UGT1A1 is known to be decreased and the metabo-
lism of SN-38 to be delayed, and serious adverse drug 
reactions such as neutropenia may occur as a result. It 
is especially desirable to test for a UGT1A1 genetic 
polymorphism before administering IRI to patients with 
a high serum bilirubin level, elderly patients, patients 
whose general condition is poor (e.g., PS2), and patients 
in whom severe toxicity (especially neutropenia) devel-
oped after the last administration of IRI. On the other 
hand, because IRI toxicity cannot be predicted with cer-
tainty on the basis of the presence of a UGT1A1 genetic 
polymorphism alone, it is essential to monitor patients’ 
general condition during treatment and manage adverse 
drug reactions carefully regardless of whether a genetic 
polymorphism is detected.
CQ-17: is hepatic arterial infusion therapy effective in 
cases of liver metastases?
•	 Comparisons between hepatic arterial infusion ther-
apy using fluoropyrimidine alone and systemic chem-
otherapy showed no clear difference in survival. The 
effectiveness of hepatic arterial infusion therapy in 
comparison with systemic chemotherapy using multi-
drug combination has not been established (recom-
mendation/evidence level 1C).
CQ-18: is preoperative chemoradiotherapy effective in 
patients with rectal cancer?
•	 In the USA and Europe, although preoperative chem-
oradiotherapy has lowered local recurrence rates in 
comparison with TME-only, reports suggest that it has 
not contributed to improved survival rates. In Japan, 
where surgical methods differ from the USA and 
Europe, the efficacy of preoperative chemoradiother-
apy has not been established in regard to rectal can-
cers in which the lower margin of the tumor is closer 
to the anus than the peritoneal reflection (evidence 
level B).
CQ-19: is chemoradiotherapy effective for unresectable 
locally advanced and locally recurrent rectal cancer?
① In cases of locally advanced and locally recurrent rec-
tal cancer determined likely to become R0 resectable 
as a result of tumor shrinkage following treatment, it 
is recommended that chemoradiotherapy, with the aim 
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of resection, be used as opposed to radiotherapy alone 
(recommendation/evidence level 1B).
② Chemoradiotherapy should also be taken into consid-
eration where the objective is relief of symptoms (rec-
ommendation/evidence level 1C).
CQ-20-1: is surveillance subsequent to curative surgery for 
colorectal cancer effective?
•	 It has been suggested that the efficacy of surveillance 
is its contribution to improving prognosis by allowing 
the early detection of recurrence, and as such, regular 
postoperative surveillance is desirable (recommenda-
tion/evidence level 1A).
•	 However, an optimal surveillance protocol incorporat-
ing the health economical point of view has not been 
sufficiently established.
CQ-20-2: is the surveillance of multiple cancers (multiple 
colorectal cancer or other organ cancer) effective subse-
quent to curative surgery for colorectal cancer?
① Metachronous colorectal cancer occurs more frequently 
in cases of colorectal cancer resection than in the general 
population, and as such, regular laparoscopic examina-
tion of the colon is recommended (recommendation/evi-
dence level 1B).
② There is no indication that post-surgical surveillance 
targeting multiple cancers is effective. The appropriate 
course of action is to educate the patient regarding the 
need for regular cancer examinations and recommend 
periodic checkups (recommendation/evidence level 2C).
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